IONIS PHARMACEUTICALS INC (IONS)

72 -1.07 (-1.46%)

As of 2025-10-16 18:39:01 EST

Ionis Pharmaceuticals, Inc. is a biotechnology that specializes in discovering and developing antisense therapy, as well as RNA interference and CRISPR therapeutics. The company was founded in 1989 is based in Carlsbad, California. The company was previously known as Isis Pharmaceuticals until December 2015.

Traded asNasdaq: IONS
ISINUS4622221004
CIK0000874015
LEI549300SI4ZGLG0BLUZ92
EIN330336973
SectorBiotechnology
IndustryPharmaceutical Preparations
CEOBrett P. Monia
Employees1,069
Fiscal Year End1231
Address2855 GAZELLE COURT, CARLSBAD, CA, 92010
Phone7609319200
Websitehttp://ionispharma.com
Stock Quotes
trading_symbolregistrant_nametimepricechangepercentage_change
IONSIONIS PHARMACEUTICALS INC2025-10-16 18:39:0172-1.07-1.46
This is a preview of the latest data. Subscribe to access the full data.
Company Information
trading_symbolcentral_index_keyregistrant_nameisin_numberlei_numberein_numberexchangesic_codesic_descriptionfiscal_year_endstate_of_incorporationaddress_streetaddress_cityaddress_stateaddress_zip_codeaddress_countryaddress_country_codephone_numbermailing_addressbusiness_addressformer_nameindustryfounding_datechief_executive_officernumber_of_employeeswebsitemarket_capshares_issuedshares_outstandingdescriptionupdate_time
IONS0000874015IONIS PHARMACEUTICALS INCUS4622221004549300SI4ZGLG0BLUZ92330336973Nasdaq2834Pharmaceutical Preparations1231CA2855 GAZELLE COURTCARLSBADCA92010UNITED STATESUS76093192002855 GAZELLE COURT, CARLSBAD, CA, 920102855 GAZELLE COURT, CARLSBAD, CA, 92010ISIS PHARMACEUTICALS INCBiotechnology1989Brett P. Monia1,069http://ionispharma.com5,738,934,243159,196,782159,391,229Ionis Pharmaceuticals, Inc. is a biotechnology that specializes in discovering and developing antisense therapy, as well as RNA interference and CRISPR therapeutics. The company was founded in 1989 is based in Carlsbad, California. The company was previously known as Isis Pharmaceuticals until December 2015.2025-10-10 19:47:44
This is a preview of the latest data. Subscribe to access the full data.
IONS Stock Price (End-of-Day)
This is a preview of the latest data. Subscribe to access the full data.
IONS Stock Price (1-Minute)
This is a preview of the latest data. Subscribe to access the full data.
Market Cap
Fiscal YearMarket CapChange In Market CapPercentage Change In Market CapShares OutstandingChange In Shares OutstandingPercentage Change In Shares Outstanding
20245,738,934,2431,495,612,83335.2463158,964,77213,212,9759.0654
20234,243,321,410438,616,67611.5283145,751,7972,797,8041.9571
20223,804,704,734-870,500,239-18.6195142,953,9931,265,2660.893
This is a preview of the latest data. Subscribe to access the full data.
Executive Compensation
Executive NameExecutive PositionFiscal YearSalaryBonusStock AwardsIncentive Plan CompensationOther CompensationTotal Compensation
Mariana BaroldiDirector2024240,76094,047236,915—17,101679,035
Mariana BaroldiDirector2023218,200104,17571,730—20,028513,949
Mariana BaroldiDirector2022204,98649,88347,139—18,773370,238
Richard S. GearyChief Development Officer, Executive Vice President2020509,360281,1671,502,162—78,3794,011,036
Elizabeth L. HougenChief Financial Officer, Executive Vice President2020499,555298,7341,663,208—63,8384,341,100
This is a preview of the latest data. Subscribe to access the full data.
Employee Count
Fiscal YearEmployee Count
20241,069
2023927
2022796
This is a preview of the latest data. Subscribe to access the full data.
Income Statements
Fiscal Year202420232022
Revenue705,138,000787,647,000587,367,000
Cost Of Revenue11,215,0009,133,00014,116,000
Gross Profit———
Research And Development Expenses901,530,000899,625,000833,147,000
General And Administrative Expenses267,474,000232,619,000150,295,000
Operating Expenses1,180,219,0001,141,377,000997,558,000
Operating Income-475,081,000-353,730,000-410,191,000
Net Income-453,897,000-366,286,000-269,722,000
Earnings Per Share Basic-3.04-2.56-1.9
Earnings Per Share Diluted-3.04-2.56-1.9
Weighted Average Shares Outstanding Basic149,514,000143,190,000141,848,000
Weighted Average Shares Outstanding Diluted149,514,000143,190,000141,848,000
This is a preview of the latest data. Subscribe to access the full data.
Balance Sheet Statements
Fiscal Year202420232022
Cash And Cash Equivalents242,077,000399,266,000276,472,000
Marketable Securities Current1,403,466,0001,311,396,0001,211,568,000
Accounts Receivable92,188,00097,778,00025,538,000
Inventories12,512,00028,425,00022,033,000
Non Trade Receivables———
Other Assets Current217,934,000184,449,000168,254,000
Total Assets Current2,620,290,0002,641,853,0002,202,694,000
Marketable Securities Non Current652,542,000653,494,000509,823,000
Property Plant And Equipment94,251,00071,043,00074,294,000
Other Assets Non Current127,278,000105,280,00075,344,000
Total Assets Non Current383,385,000348,219,000331,182,000
Total Assets3,003,675,0002,990,072,0002,533,876,000
Accounts Payable42,964,00026,027,00017,921,000
Deferred Revenue78,989,000151,128,00090,577,000
Short Term Debt165,000157,000151,000
Other Liabilities Current9,279,0008,831,0007,535,000
Total Liabilities Current309,318,000448,090,000311,561,000
Long Term Debt1,253,062,0001,308,360,0001,194,233,000
Other Liabilities Non Current——7,126,000
Total Liabilities Non Current1,949,502,0001,914,112,0001,361,660,000
Total Liabilities2,415,324,0002,603,386,0001,960,989,000
Common Stock158,000144,000142,000
Retained Earnings-2,200,000,000-1,795,911,000-1,429,625,000
Accumulated Other Comprehensive Income-30,811,000-32,645,000-57,480,000
Total Shareholders Equity600,000,000386,686,000572,887,000
This is a preview of the latest data. Subscribe to access the full data.
Cash Flow Statements
Fiscal Year202420232022
Depreciation And Amortization9,614,00010,292,00014,328,000
Share Based Compensation Expense130,200,000105,809,000100,264,000
Other Non Cash Income Expense———
Change In Accounts Receivable———
Change In Inventories5,071,0006,392,000-2,773,000
Change In Non Trade Receivables———
Change In Other Assets25,857,00029,840,00024,682,000
Change In Accounts Payable15,990,0008,119,0001,094,000
Change In Other Liabilities———
Cash From Operating Activities-500,947,000-307,513,000-274,370,000
Purchases Of Marketable Securities1,852,858,0001,770,814,0001,485,772,000
Sales Of Marketable Securities1,769,172,0001,584,676,000989,152,000
Acquisition Of Property Plant And Equipment45,280,00023,805,00015,721,000
Acquisition Of Business———
Other Investing Activities———
Cash From Investing Activities-134,027,000-214,127,000-262,636,000
Tax Withholding For Share Based Compensation0010,953,000
Payments Of Dividends———
Issuance Of Common Stock489,120,000——
Repurchase Of Common Stock——0
Issuance Of Long Term Debt———
Repayment Of Long Term Debt———
Other Financing Activities33,609,00049,442,0006,373,000
Cash From Financing Activities478,058,000644,082,000-55,295,000
Change In Cash-157,189,000122,794,000-592,719,000
Cash At End Of Period242,077,000399,266,000276,472,000
Income Taxes Paid-5,620,00048,334,0005,010,000
Interest Paid10,869,0006,512,0002,898,000
This is a preview of the latest data. Subscribe to access the full data.
Key Metrics
Fiscal Year202420232022
Earnings Per Share-3.04-2.56-1.9
Price To Earnings Ratio-11.5-19.7617-19.8789
Earnings Growth Rate18.7534.7368850
Price Earnings To Growth Ratio-0.6133-0.5689-0.0234
Book Value Per Share3.93512.70054.0387
Price To Book Ratio8.884218.73359.3519
Ebitda-432,909,000-295,000,000-242,262,000
Enterprise Value6,238,159,4408,153,233,1006,275,510,960
Dividend Yield———
Dividend Payout Ratio———
Debt To Equity Ratio2.08873.38392.0849
Capital Expenditures32,822,0007,041,000-89,447,000
Free Cash Flow-533,769,000-314,554,000-184,923,000
Return On Equity-0.7565-0.9472-0.4708
One Year Beta0.74910.57270.9009
Three Year Beta0.80070.86430.8871
Five Year Beta0.85060.86920.9477
This is a preview of the latest data. Subscribe to access the full data.
Insider Transactions
Insider NameRelationship To IssuerTransaction DateAmount Of SecuritiesAcquired Or DisposedSecurities Owned Following Transaction
Devers Shannon L.EVP, Chief Human Resources Ofc2025-10-161,263D17,494
Swayze EricEVP Research2025-10-1653D256
Birchler BrianEVP, Corp and Development Ops2025-10-1512,425A69,251
Birchler BrianEVP, Corp and Development Ops2025-10-1512,425D56,826
Birchler BrianEVP, Corp and Development Ops2025-10-1512,425D0
This is a preview of the latest data. Subscribe to access the full data.
Senate Trading
Name Of Reporting PersonType Of Reporting PersonReport DateTransaction TypeTransaction DateOwner TypeAmount
Sheldon WhitehouseSenator2016-02-23Sale (Full)2016-01-20Self$1,001 - $15,000
This is a preview of the latest data. Subscribe to access the full data.
House Trading
Name Of Reporting PersonReport DateStateTransaction TypeTransaction DateOwner TypeAmount
Daniel Goldman2023-04-17NY10Sale2023-03-06—$1,001 - $15,000
This is a preview of the latest data. Subscribe to access the full data.
Institutional Holdings
Investor NamePeriod Of ReportMarket ValueAmount Of SecuritiesPrice Per Security
Capital Advisors, Ltd. LLC2025-09-3019,00029564.4068
Blue Trust, Inc.2025-09-306541065.4
CWM, LLC2025-09-30163,0002,48865.5145
Global X Japan Co., Ltd.2025-09-3021,00032165.4206
DAVENPORT & Co LLC2025-09-304,092,87162,56365.42
This is a preview of the latest data. Subscribe to access the full data.
Mutual Fund Holdings
Registrant NamePeriod Of ReportFund NameFund SymbolAmount Of UnitsValue In UsdPercentage Value Compared To Assets
ETFis Series Trust I2025-07-31Virtus LifeSci Biotech Products ETFBBP12,476536,218.482.1757
AMG Funds IV2025-07-31CLASS Z SHARESACWZX11,051474,971.981.3122
AMG Funds IV2025-07-31CLASS I SHARESACWIX11,051474,971.981.3122
AMG Funds IV2025-07-31CLASS N SHARESACWDX11,051474,971.981.3122
Advisors' Inner Circle Fund III2025-07-31I SharesKCXIX69129,699.180.0122
This is a preview of the latest data. Subscribe to access the full data.